Not recruiting

Study on the Effectiveness and Safety of Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone for Patients with Newly Diagnosed Multiple Myeloma

Verified siteRegistered drugNo placebo

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying a condition called Multiple Myeloma, which is a type of cancer that affects plasma cells in the bone marrow. The study is specifically for patients who have been newly diagnosed with this disease. The treatment being tested is a combination of four medications: Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone. Isatuximab is given as a solution for infusion, which means it is administered directly into the bloodstream through a vein. Lenalidomide is provided in the form of hard capsules, Bortezomib is a powder that is mixed into a solution for injection, and Dexamethasone is available as tablets.

The purpose of this study is to evaluate how effective and safe this combination of medications is for treating Multiple Myeloma. Participants in the study will receive these medications over a period of time, and their health will be monitored to see how well the treatment works and to check for any side effects. The study will look at how many patients achieve a significant reduction in their cancer after two cycles of treatment, which is referred to as a "Very Good Partial Response" or better. This will help researchers understand the potential benefits of the treatment.

Throughout the study, participants will undergo regular health assessments to track their progress. The study will also gather information on the overall response to the treatment, the time it takes to see improvements, and the safety of the medication combination. This research aims to provide valuable insights into the treatment of Multiple Myeloma and improve outcomes for patients with this condition.

The research process

The trial runs in 4 steps – from screening to follow-up. Each step says what happens and what the team monitors.

Step 1
Induction treatment
The induction phase involves a combination of medications to treat newly diagnosed multiple myeloma.
Medications include dexamethasone (2 mg tablets taken orally), bortezomib (1 mg powder for solution administered subcutaneously), lenalidomide (10 mg hard capsules taken orally), and isatuximab (solution for infusion administered intravenously).
The goal is to achieve a very good partial response or better by the end of two cycles.
Step 2
Maintenance therapy
Following the induction phase, maintenance therapy is administered to sustain the response.
Medications include lenalidomide in varying dosages (15 mg and 25 mg hard capsules taken orally).
The therapy aims to maintain the response achieved during induction and improve overall outcomes over one to two years.
Step 3
Assessment and monitoring
Throughout the trial, regular assessments are conducted to monitor the response to treatment.
These assessments include measuring the rate of very good partial response or better, complete response, and stringent complete response.
Safety and tolerability of the treatment regimen are also evaluated.
Step 4
Completion and follow-up
Upon completion of the treatment phases, follow-up assessments are conducted to evaluate long-term outcomes.
These include progression-free survival, overall survival, and duration of response.
The trial is estimated to conclude by June 2028.

Who can join the trial?

14 criteria

The patient must have been previously diagnosed with **Multiple Myeloma (MM)**, which is a type of blood cancer, based on standard criteria and currently needs treatment.
The patient must provide voluntary written informed consent, which means they agree to participate in the study after understanding the details, and they can withdraw at any time without affecting their future medical care.
The patient must be between **18 and 75 years old**. Patients over 70 need special approval.
The patient must have a measurable disease, which means having certain levels of specific proteins in the blood or urine that can be measured.
The patient must have certain laboratory test results, such as:
- **ANC** (a type of white blood cell count) of at least 1,000 cells/dL.
- **Platelet count** of at least 75,000 cells/dL if less than 50% of bone marrow cells are plasma cells, or at least 30,000 cells/dL if 50% or more are plasma cells.
- **Total bilirubin** level within 2 times the normal limit, except for patients with Gilbert Syndrome, who can have up to 3.0 mg/dL.
- **AST** and **ALT** (liver enzymes) within 3 times the normal limit.
- **Hemoglobin** level of at least 8g/dL.
- **Calculated CrCl** (a measure of kidney function) of at least 30 mL/min.
- The patient must have an **ECOG performance status** of 2 or less, which is a scale that measures how well a patient can perform daily activities.
- The patient must agree to join a mandatory **Risk Management Programme** for a medication called Lenalidomide and be willing to follow the programme's requirements.
- The patient must be able to understand and willing to sign a written informed consent document.
- The patient must be considered eligible for **ASCT** (Autologous Stem Cell Transplant) by their doctor.

Who cannot join the trial?

4 criteria

Patients who have not been newly diagnosed with Multiple Myeloma cannot participate. Multiple Myeloma is a type of cancer that affects certain cells in the bone marrow.
Patients who are not within the specified age range for the study cannot participate. The age range is typically defined by the study organizers.
Patients who belong to a vulnerable population, which means they might need special protection or care, cannot participate.
Patients who do not meet the specific health conditions or requirements set by the study cannot participate.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Region Midtjylland
Responsive
Aarhus, Denmark
University Hospital Galway
Verified
Galway, Ireland
University Hospital Limerick
Verified
Limerick, Ireland

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting

Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

Isatuximab
is a medication used in this study to help treat multiple myeloma. It works by targeting and attaching to a specific protein on the surface of cancer cells, which helps the immune system to identify and destroy these cells.
Lenalidomide
is a drug that helps to slow down or stop the growth of cancer cells. It also helps the immune system to attack cancer cells more effectively. It is commonly used in the treatment of multiple myeloma.
Bortezomib
is a medication that interferes with the growth of cancer cells and is used to treat multiple myeloma. It works by blocking the action of proteasomes, which are structures inside cells that break down proteins. This can lead to the death of cancer cells.
Dexamethasone
is a type of steroid that is used to reduce inflammation and suppress the immune system. In the context of multiple myeloma, it helps to enhance the effects of other cancer treatments and can also help to reduce some of the symptoms associated with the disease.

What is already known about the treatment

Isatuximab
Isatuximab is administered intravenously and is currently being studied in clinical trials for its effectiveness in treating newly diagnosed multiple myeloma. It is a monoclonal antibody that targets a specific protein on the surface of cancer cells, helping the immune system to identify and destroy these cells. Isatuximab is classified as an anti-cancer agent and is part of a combination therapy aimed at improving patient outcomes in multiple myeloma.
Lenalidomide
Lenalidomide is taken orally and is widely used in the treatment of multiple myeloma, often in combination with other medications. It works by modulating the immune system and inhibiting the growth of cancer cells. Lenalidomide is classified as an immunomodulatory drug and is a key component in the therapeutic regimen for multiple myeloma.
Bortezomib
Bortezomib is administered via injection and is an established treatment for multiple myeloma. It functions by inhibiting proteasomes, which are enzyme complexes that break down proteins in cells, leading to cancer cell death. Bortezomib is classified as a proteasome inhibitor and is used to manage and treat multiple myeloma effectively.
Dexamethasone
Dexamethasone is taken orally or intravenously and is commonly used in combination with other drugs to treat multiple myeloma. It is a corticosteroid that reduces inflammation and suppresses the immune response, helping to control symptoms and enhance the effectiveness of other cancer treatments. Dexamethasone is classified as a corticosteroid and plays a supportive role in cancer therapy.

Investigated diseases

Multiple Myeloma – Multiple Myeloma is a type of blood cancer that affects plasma cells, which are a kind of white blood cell found in the bone marrow. In this disease, abnormal plasma cells multiply and produce a large amount of a single type of antibody, which can cause damage to bones, kidneys, and the immune system. As the disease progresses, it can lead to symptoms such as bone pain, frequent infections, anemia, and kidney problems. The accumulation of these abnormal cells can form tumors in bones or soft tissues. Over time, the disease can cause significant damage to the skeletal system and other organs. It is a chronic condition that often requires ongoing management to control symptoms and progression.